3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
20
Breast Neoplasms
6
Polycystic Ovary Syndrome
4
Infertility
4
Uterine Anomalies
1
Sleep Wake Disorders
1
Salpingitis
1
Salivary Gland Neoplasms
1
Primary Ovarian Insufficiency
1
Pregnancy, Ectopic
1
Neoplasm Metastasis
1
Myofibroma
1
Metabolic Syndrome
1
Lymphoma
1
Leiomyoma
1
Infertility, Female
1
Hypogonadism
1
Hodgkin Disease
1
Fatty Liver
1
Fatigue
1
Endometritis
1
Endometriosis
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Invasive Nos
1
Adenocarcinoma
1
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Triptorelin Pamoate
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Cancer Invasive Nos
×
Triptorelin Pamoate
×
Clear all
NCT02005887
2019-05-29
TREND
ETOP IBCSG Partners Foundation
Phase 2
Completed
51 enrolled
10 charts